Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Melanoma 1Anus Neoplasms 1

Interventions

Cyclophosphamide 3fludarabine 2aldesleukin 2Fluorouracil 2spartalizumab 1niraparib 1fludarabine phosphate 1entinostat 1bintrafusp alfa protein, human 1Tomography, X-Ray Computed 1Therapeutics 1SRA737 1Papillomavirus Vaccines 1NHS-IL12 immunocytokine 1Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin 1Mitomycin 1Magnetic Resonance Imaging 1Leucovorin 1Interleukin-2 1Ibuprofen 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Biopsy 1Adoptive Transfer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anus Neoplasms × Adoptive Transfer × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡